458 related articles for article (PubMed ID: 25338271)
1. The use of dietary supplements to alleviate androgen deprivation therapy side effects during prostate cancer treatment.
Dueregger A; Heidegger I; Ofer P; Perktold B; Ramoner R; Klocker H; Eder IE
Nutrients; 2014 Oct; 6(10):4491-519. PubMed ID: 25338271
[TBL] [Abstract][Full Text] [Related]
2. Promoting calcium and vitamin D intake to reduce the risk of osteoporosis in men on androgen deprivation therapy for recurrent prostate cancer.
Davison BJ; Wiens K; Cushing M
Support Care Cancer; 2012 Oct; 20(10):2287-94. PubMed ID: 22138848
[TBL] [Abstract][Full Text] [Related]
3. Osteoporosis from androgen deprivation therapy in prostate cancer treatment.
McLeod N; Huynh CC; Rashid P
Aust Fam Physician; 2006 Apr; 35(4):243-5. PubMed ID: 16642243
[TBL] [Abstract][Full Text] [Related]
4. Calcium and vitamin D supplementation during androgen deprivation therapy for prostate cancer: a critical review.
Datta M; Schwartz GG
Oncologist; 2012; 17(9):1171-9. PubMed ID: 22836449
[TBL] [Abstract][Full Text] [Related]
5. Nutrition education for osteoporosis prevention in men with prostate cancer initiating androgen deprivation therapy.
Millar H; Davison J
Clin J Oncol Nurs; 2012 Oct; 16(5):497-503. PubMed ID: 23022933
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation therapy: evidence-based management of side effects.
Ahmadi H; Daneshmand S
BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
[TBL] [Abstract][Full Text] [Related]
8. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
[TBL] [Abstract][Full Text] [Related]
9. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer.
Nadler M; Alibhai S; Catton P; Catton C; To MJ; Jones JM
BJU Int; 2013 Jun; 111(8):1301-9. PubMed ID: 23351062
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis and prostate cancer: a cross-sectional study of Danish men with prostate cancer before androgen deprivation therapy.
Poulsen MH; Frost M; Abrahamsen B; Brixen K; Walter S
Scand J Urol; 2014 Aug; 48(4):350-5. PubMed ID: 24548220
[TBL] [Abstract][Full Text] [Related]
12. The role of exercise in the management of adverse effects of androgen deprivation therapy for prostate cancer: a rapid review.
Edmunds K; Tuffaha H; Scuffham P; Galvão DA; Newton RU
Support Care Cancer; 2020 Dec; 28(12):5661-5671. PubMed ID: 32699997
[TBL] [Abstract][Full Text] [Related]
13. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.
Grossmann M; Hamilton EJ; Gilfillan C; Bolton D; Joon DL; Zajac JD
Med J Aust; 2011 Mar; 194(6):301-6. PubMed ID: 21426285
[TBL] [Abstract][Full Text] [Related]
14. Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL; Alibhai SM; Basaria S; D'Amico AV; Kantoff PW; Keating NL; Penson DF; Rosario DJ; Tombal B; Smith MR
Eur Urol; 2015 May; 67(5):825-36. PubMed ID: 25097095
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy.
Lassemillante AC; Doi SA; Hooper JD; Prins JB; Wright OR
Endocrine; 2015 Nov; 50(2):344-54. PubMed ID: 25636442
[TBL] [Abstract][Full Text] [Related]
16. Managing complications of androgen deprivation therapy for prostate cancer.
Holzbeierlein JM
Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
[TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of androgen deprivation therapy in prostate cancer patients.
Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
[TBL] [Abstract][Full Text] [Related]
19. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.
Taylor LG; Canfield SE; Du XL
Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.
Malcolm JB; Derweesh IH; Kincade MC; DiBlasio CJ; Lamar KD; Wake RW; Patterson AL
Can J Urol; 2007 Jun; 14(3):3551-9. PubMed ID: 17594745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
